Updated Jul 15, 7:15 PM · 60 sources analyzed
Key Takeaways
Levomecor terminated both Phase 3 REL-1017 MDD trials simultaneously, effectively ending the program without releasing efficacy data.
CMS proposed banning third-party RPM vendors under Medicare, a structurally disruptive policy shift for digital health and decentralized trial models.
Crinetics and Intercept each recorded Phase 3 terminations — paltusotine in acromegaly and OCA in pediatric biliary atresia — without disclosing outcome data.
🏆 Winner
Ascendis Pharma — Phase 3 TransCon CNP study in achondroplasia completed, positioning the company for a potential regulatory filing in a rare pediatric indication
📉 Loser
Levomecor Inc. — simultaneous termination of two Phase 3 trials of REL-1017 in MDD with no efficacy data disclosed effectively ends the program
🔭 Watch Next
Levomecor, Crinetics, and Intercept each owe the market an explanation for their respective Phase 3 terminations; the first substantive company statement disclosing the termination rationale — safety signal, futility, or strategic — will be the most important near-term information event from today's sources.
Medicare proposes ban on third-party remote monitoring vendors
CMS proposed on July 15 to prohibit vendors from delivering remote patient monitoring (RPM) services on behalf of physicians under Medicare, a structural policy shift that would require physicians to directly employ or supervise monitoring personnel. The proposal targets a rapidly growing but scrutiny-laden care model where vendor-driven billing has drawn fraud concerns, and if finalized it would dismantle the business model of numerous RPM companies operating at scale. For digital health and RPM-adjacent biotech companies — including those embedding monitoring into decentralized trial infrastructure — this signals a tightening regulatory posture that could reshape how remote data collection is reimbursed across both care delivery and clinical research.
STAT News ↗CMS proposes to ban third-party vendors from delivering remote patient monitoring (RPM) services under Medicare, requiring physician-direct oversight of all monitoring activities.
If finalized, this rule would eliminate the vendor-intermediary model that underpins most commercial RPM businesses, forcing physicians to internalize monitoring operations or exit the service — a structural disruption for digital health companies embedded in this care model.
Why it matters
This proposal is a significant regulatory risk event for RPM-reliant digital health companies and any biotech or MedTech firm using vendor-run remote monitoring in decentralized trial infrastructure; the comment period and finalization timeline will determine urgency, but companies should be stress-testing their reimbursement and trial-operations models now. BD teams evaluating digital health partnerships should treat this as a material overhang.
What to watch
Watch for the CMS comment period deadline and any finalization timeline in the 2027 Physician Fee Schedule rulemaking cycle, and whether major health system or digital health industry groups mount a formal regulatory challenge.
Levomecor Inc.
REL-1017 in Major Depressive Disorder (MDD)
Two Phase 3 randomized, double-blind, placebo-controlled trials of REL-1017 as adjunctive therapy for MDD (NCT04855747 and NCT06011577) have been marked Terminated on ClinicalTrials.gov. No efficacy or safety outcome data have been released in conjunction with the terminations.
Why it matters
Two simultaneous Phase 3 terminations without a disclosed efficacy signal is a decisive program-ending event for REL-1017; without a data readout explaining the rationale, investors and partners have no basis to assess whether the molecule failed on efficacy, safety, or feasibility grounds. The company will need to provide transparency on the termination rationale before any pipeline residual value can be assigned.
What to watch
Watch for a company statement or regulatory filing from Levomecor explaining the termination rationale — particularly whether a safety signal or interim futility analysis drove the decision — as that will determine whether any residual asset value exists.
Ascendis Pharma
TransCon CNP in Achondroplasia
The Phase 2/3 trial of TransCon CNP (once-weekly subcutaneous 100 µg/kg) versus placebo over 52 weeks in children with achondroplasia (NCT05598320) is now marked Completed on ClinicalTrials.gov. The registry update does not include annualized growth velocity results or other efficacy data.
Why it matters
The trial completion is a procedural update, not a data readout; Ascendis must now demonstrate that TransCon CNP's once-weekly dosing profile offers a clinically or commercially meaningful advantage over BioMarin's daily vosoritide to justify physician and payer uptake. The growth velocity result, when disclosed, will be the key differentiating number.
What to watch
Watch for Ascendis to release topline annualized growth velocity data and any superiority or non-inferiority claim versus the vosoritide historical benchmark, likely at a pediatric endocrinology or rare disease conference in late 2026.
Crinetics Pharmaceuticals
Paltusotine in Acromegaly
A randomized, placebo-controlled Phase 3 study of paltusotine — an oral, non-peptide somatostatin agonist — in acromegaly (NCT04837040) has been marked Terminated on ClinicalTrials.gov. No efficacy or safety outcome data accompany the registry update.
Why it matters
A Phase 3 termination in acromegaly without disclosed data raises immediate questions for Crinetics' investment thesis, particularly given that paltusotine was being positioned to replace injectable somatostatin analogs; the company will need to clarify whether this reflects a strategic reprioritization or a clinical setback, and the impact on their broader pipeline credibility will depend on that explanation.
What to watch
Watch for a Crinetics investor communication or SEC filing clarifying the termination rationale, and whether any paltusotine development in other indications or dosing regimens will continue.
Two Phase 3 randomized, double-blind, placebo-controlled trials of REL-1017 as adjunctive therapy for MDD (NCT04855747 and NCT06011577) have been marked Terminated on ClinicalTrials.gov. No efficacy or safety outcome data have been released in conjunction with the terminations.
Why it matters
The back-to-back termination of both Phase 3 studies effectively ends REL-1017's late-stage development path in MDD, removing a potential entrant from the adjunctive antidepressant space.
Analysis
Two simultaneous Phase 3 terminations without a disclosed efficacy signal is a decisive program-ending event for REL-1017; without a data readout explaining the rationale, investors and partners have no basis to assess whether the molecule failed on efficacy, safety, or feasibility grounds. The company will need to provide transparency on the termination rationale before any pipeline residual value can be assigned.
What to watch
Watch for a company statement or regulatory filing from Levomecor explaining the termination rationale — particularly whether a safety signal or interim futility analysis drove the decision — as that will determine whether any residual asset value exists.
A multicenter, randomized, double-blind, placebo-controlled 6-week Phase 3 trial of AMZ001 once daily in knee osteoarthritis (NCT06693648) has been marked Completed on ClinicalTrials.gov. No efficacy or safety outcome data have been released alongside the registry update.
Why it matters
Phase 3 completion in knee osteoarthritis is a meaningful logistical milestone for Amzell, but without outcome data the competitive relevance of AMZ001 in a crowded pain-management space cannot be assessed.
Analysis
Amzell is a private, under-the-radar company in a pain indication crowded with both pharma and non-pharma entrants; the completion of a blinded Phase 3 in just 6 weeks of treatment suggests the primary endpoint is likely symptom-based, and the readout will need to show a clinically meaningful pain reduction — not just statistical separation — to attract partnership interest.
What to watch
Watch for Amzell to publish topline Phase 3 data or present at a pain or rheumatology conference in the second half of 2026, which would be the first efficacy signal for this asset.
The Phase 2/3 trial of TransCon CNP (once-weekly subcutaneous 100 µg/kg) versus placebo over 52 weeks in children with achondroplasia (NCT05598320) is now marked Completed on ClinicalTrials.gov. The registry update does not include annualized growth velocity results or other efficacy data.
Why it matters
Completion of this pivotal-stage study positions Ascendis for a potential regulatory filing, but the competitive window is tightening as BioMarin's vosoritide (Voxzogo) is already approved in the indication.
Analysis
The trial completion is a procedural update, not a data readout; Ascendis must now demonstrate that TransCon CNP's once-weekly dosing profile offers a clinically or commercially meaningful advantage over BioMarin's daily vosoritide to justify physician and payer uptake. The growth velocity result, when disclosed, will be the key differentiating number.
What to watch
Watch for Ascendis to release topline annualized growth velocity data and any superiority or non-inferiority claim versus the vosoritide historical benchmark, likely at a pediatric endocrinology or rare disease conference in late 2026.
A randomized, placebo-controlled Phase 3 study of paltusotine — an oral, non-peptide somatostatin agonist — in acromegaly (NCT04837040) has been marked Terminated on ClinicalTrials.gov. No efficacy or safety outcome data accompany the registry update.
Why it matters
Termination of Crinetics' Phase 3 paltusotine study in acromegaly removes what had been a potential first oral somatostatin receptor agonist from the late-stage pipeline for this rare endocrine tumor condition.
Analysis
A Phase 3 termination in acromegaly without disclosed data raises immediate questions for Crinetics' investment thesis, particularly given that paltusotine was being positioned to replace injectable somatostatin analogs; the company will need to clarify whether this reflects a strategic reprioritization or a clinical setback, and the impact on their broader pipeline credibility will depend on that explanation.
What to watch
Watch for a Crinetics investor communication or SEC filing clarifying the termination rationale, and whether any paltusotine development in other indications or dosing regimens will continue.
A Phase 2/3 study evaluating OCA in pediatric patients with biliary atresia following hepatoportoenterostomy (the Kasai procedure) — NCT06121375 — has been marked Terminated on ClinicalTrials.gov. No efficacy, safety, or pharmacokinetic data are disclosed in the registry update.
Why it matters
Termination of the pediatric biliary atresia program closes another potential extension pathway for OCA following the FDA's prior rejection of OCA in primary biliary cholangitis, further narrowing Intercept's clinical optionality.
Analysis
This termination, in the context of Intercept's broader regulatory and commercial difficulties with OCA, suggests the company is actively pruning its pipeline rather than advancing it; for any acquirer or partner evaluating Intercept's remaining assets, this is a further negative signal on OCA's versatility and the company's development execution.
What to watch
Watch for Intercept to provide strategic pipeline guidance clarifying what, if anything, remains in active development for OCA or their next-generation bile acid programs, likely at a forthcoming investor event or earnings call.
CMS proposes to ban third-party vendors from delivering remote patient monitoring (RPM) services under Medicare, requiring physician-direct oversight of all monitoring activities.
Why it matters
If finalized, this rule would eliminate the vendor-intermediary model that underpins most commercial RPM businesses, forcing physicians to internalize monitoring operations or exit the service — a structural disruption for digital health companies embedded in this care model.
Analysis
This proposal is a significant regulatory risk event for RPM-reliant digital health companies and any biotech or MedTech firm using vendor-run remote monitoring in decentralized trial infrastructure; the comment period and finalization timeline will determine urgency, but companies should be stress-testing their reimbursement and trial-operations models now. BD teams evaluating digital health partnerships should treat this as a material overhang.
What to watch
Watch for the CMS comment period deadline and any finalization timeline in the 2027 Physician Fee Schedule rulemaking cycle, and whether major health system or digital health industry groups mount a formal regulatory challenge.
Ketamine-enhanced prolonged exposure therapy studied for PTSD in veterans
A VA-sponsored Phase 2 study evaluating repeated-dose ketamine combined with prolonged exposure therapy versus placebo in veterans with PTSD has been marked Completed on ClinicalTrials.gov (NCT04560660); no outcome data have been released.
Why it matters
If the combination shows additive benefit over exposure therapy alone, it would provide a pharmacological rationale for pairing NMDA receptor antagonists with structured psychotherapy — a model with broader applicability across trauma-related disorders.
Analysis
The ketamine-plus-psychotherapy combination approach is gaining traction across multiple sponsors; the VA study's eventual data will be closely watched by companies developing ketamine analogs, psychedelic-assisted therapy programs, and PTSD-focused CNS developers as a signal of whether the pharmacotherapy-plus-behavioral pairing has reproducible utility beyond anecdote.
What to watch
Watch for the VA or investigators to publish results from NCT04560660 in a peer-reviewed journal or present at a psychiatry conference, which will be the first controlled signal on this specific combination regimen.
Ruxolitinib Phase 1/2 in relapsed/refractory immune bone marrow failure opens at NHLBI
The NHLBI is running an active Phase 1/2 study of ruxolitinib — a JAK1/2 inhibitor that suppresses immune signaling — in patients with relapsed or refractory severe aplastic anemia, single lineage cytopenias, T-cell large granular lymphocytic leukemia (T-LGL), and hypoplastic myelodysplastic syndrome (NCT05998408), currently active and not recruiting.
Why it matters
Demonstrating ruxolitinib activity across this heterogeneous group of immune-mediated bone marrow failure syndromes could validate JAK inhibition as a shared pathological target and open regulatory pathways for both ruxolitinib and next-generation JAK inhibitors in underserved rare hematology indications.
Analysis
For companies with JAK inhibitors in their portfolios — including Incyte, which markets ruxolitinib — positive NHLBI data could de-risk label expansion filings in bone marrow failure without requiring proprietary Phase 3 investment; competitors developing targeted immunosuppression for aplastic anemia should track this as a potential new standard-of-care challenger.
What to watch
Watch for NHLBI investigators to present interim response rate and safety data at ASH 2026 or a comparable hematology meeting, which would provide the first organized efficacy signal for ruxolitinib across this spectrum of immune bone marrow failure.
Etigilimab plus nivolumab combination tested in platinum-resistant ovarian cancer
MD Anderson's Phase 2 EON study (NCT05715216) is actively evaluating etigilimab — an anti-TIGIT antibody (a checkpoint target distinct from PD-1/PD-L1) — combined with the PD-1 inhibitor nivolumab in patients with platinum-resistant clear cell ovarian, fallopian tube, and primary peritoneal cancers; the trial is active but not recruiting.
Why it matters
TIGIT plus PD-1 co-blockade in platinum-resistant ovarian cancer, a setting with very poor prognosis and limited approved options, would provide human proof-of-concept data for TIGIT as a relevant target in gynecologic oncology — informing the field after mixed results in other solid tumor TIGIT programs.
Analysis
The TIGIT field suffered significant setbacks when tiragolumab and vibostolimab failed in lung cancer; data from EON in the distinct biology of clear cell ovarian cancer — which has high immune infiltration — could help answer whether TIGIT's value is indication-specific rather than broadly negative, with implications for companies still running TIGIT programs.
What to watch
Watch for MD Anderson to present response rate and durability data from the EON study at ASCO or SGO in 2026–2027, which will be a meaningful test of whether TIGIT blockade can find a viable clinical niche in gynecologic oncology.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
No coverage today
None of your tracked companies appeared in today's sources.